LEADER 03906nam 2200601Ia 450 001 9910809498803321 005 20200520144314.0 010 $a1-283-28323-9 010 $a9786613283238 010 $a1-4443-4634-2 010 $a1-4443-4631-8 035 $a(CKB)2550000000054394 035 $a(EBL)819327 035 $a(OCoLC)758981647 035 $a(SSID)ssj0000607896 035 $a(PQKBManifestationID)11407859 035 $a(PQKBTitleCode)TC0000607896 035 $a(PQKBWorkID)10591206 035 $a(PQKB)10532292 035 $a(MiAaPQ)EBC819327 035 $a(EXLCZ)992550000000054394 100 $a20110418d2012 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aAdvanced therapy for hepatitis C /$fedited by Geoffrey W. McCaughan, John G. McHutchison, Jean-Michel Pawlotsky 205 $a1st ed. 210 $aChichester, West Sussex $cWiley-Blackwell$d2012 215 $a1 online resource (233 p.) 300 $aDescription based upon print version of record. 311 $a1-4051-8745-X 320 $aIncludes bibliographical references and index. 327 $aAdvanced Therapy for Hepatitis C; Contents; Contributors; Preface; Section I Foundations for Understanding Antiviral Therapies in HCV; 1 HCV Replication; 2 Hepatitis C Virus Genotypes; 3 Immune Responses to HCV: Implications for Therapy; 4 Mechanisms of Action of Antiviral Drugs: The Interferons; 5 Pharmacology and Mechanisms of Action of Antiviral Drugs: Ribavirin Analogs; 6 Pharmacology and Mechanisms of Action of Antiviral Drugs: Polymerase Inhibitors; 7 Pharmacology and Mechanisms of Action of Antiviral Drugs: Protease Inhibitors; 8 Measuring Antiviral Responses 327 $aSection II Efficacy and Clinical Use of Antiviral Therapies9 Genotype 1: Standard Treatment; 10 Individually Tailored Treatment Strategies in Treatment-nai?ve Chronic Hepatitis C Genotype 1 Patients; 11 Genotype 1 Relapsers and Non-responders; 12 Standard Therapy for Genotypes 2/3; 13 Altered Dosage or Durations of Current Antiviral Therapy for HCV Genotypes 2 and 3; 14 Genotypes 2 and 3 Relapse and Non-response; 15 Hepatitis C Genotype 4 Therapy: Progress and Challenges; 16 Antivirals in Acute Hepatitis C; 17 Antivirals in Cirrhosis and Portal Hypertension 327 $a18 Treatment of Recurrent Hepatitis C Following Liver Transplantation19 Antiviral Treatment in Chronic Hepatitis C Virus Infection with Extrahepatic Manifestations; 20 Cytopenias: How they Limit Therapy and Potential Correction; 21 The Problem of Insulin Resistance and its Effect on Therapy; 22 HIV and Hepatitis C Co-infection; 23 HCV and Racial Differences; 24 HCV and the Pediatric Population; 25 New Horizons: IL28, Direct-acting Antiviral Therapy for HCV; Index 330 $aHepatologists, both researchers and front-line clinicians, now have a comprehensive guide to the treatment of patients with the HCV virus. This book focuses mainly on the efficacy and clinical use of antiviral therapies, including the use of antivirals post liver transplantation and in the presence of the HIV virus. It also explores the foundations for understanding antiviral therapies in HCV, such as the complex pharmacology and mechanisms of antiviral drugs. A 'late-breaking information' chapter contains the most recent trial results on the latest antiviral drugs. 606 $aHepatitis C$xTreatment 606 $aAntiviral agents 615 0$aHepatitis C$xTreatment. 615 0$aAntiviral agents. 676 $a616.3/62306 701 $aMcCaughan$b Geoffrey W$01670559 701 $aMcHutchison$b J. G$01763230 701 $aPawlotsky$b Jean-Michel$01670561 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910809498803321 996 $aAdvanced therapy for hepatitis C$94203559 997 $aUNINA